Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BNT25006
- Development stage
- Preclinical
- Lead developer
- BioNxt Solutions
- Modality
- Small Molecules, Drug Delivery Systems
01
Overview
**BNT25006** is an advanced-preclinical BioNxt Solutions oncology program described as a targeted chemotherapy platform incorporating an anticancer small-molecule inhibitor of mechanistic target of rapamycin. The platform is intended to improve targeted delivery of cytotoxic therapies and is reported to be adaptable to more than 100 cytotoxic agents; however, the specific cytotoxic payloads, delivery construct, formulation, route of administration, and detailed molecular pharmacology have not been publicly disclosed. Public drug-development listings identify BNT-25006 as a BioNxt mTOR-inhibitor program for neoplasms at the preclinical stage. ([synapse.patsnap.com](https://synapse.patsnap.com/drug/174d049538cd4ea1a5f8a919b2a712eb))
02
Targets
mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on BNT25006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BNT25006.